Prudential Financial Inc. lifted its holdings in Exact Sciences Corporation (NASDAQ:EXAS) by 9.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,159 shares of the medical research company’s stock after buying an additional 1,018 shares during the quarter. Prudential Financial Inc.’s holdings in Exact Sciences Corporation were worth $430,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of EXAS. Fortaleza Asset Management Inc. purchased a new stake in shares of Exact Sciences Corporation in the second quarter worth approximately $106,000. Financial Architects Inc raised its holdings in shares of Exact Sciences Corporation by 90.0% in the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after buying an additional 2,035 shares during the period. Teacher Retirement System of Texas purchased a new stake in shares of Exact Sciences Corporation in the first quarter worth approximately $203,000. Ameritas Investment Partners Inc. raised its holdings in shares of Exact Sciences Corporation by 455.0% in the first quarter. Ameritas Investment Partners Inc. now owns 9,129 shares of the medical research company’s stock worth $216,000 after buying an additional 7,484 shares during the period. Finally, Trexquant Investment LP purchased a new stake in shares of Exact Sciences Corporation in the second quarter worth approximately $216,000. Hedge funds and other institutional investors own 85.22% of the company’s stock.

Several equities research analysts have recently weighed in on the company. Robert W. Baird reiterated a “buy” rating and issued a $49.00 price target on shares of Exact Sciences Corporation in a report on Friday, October 6th. Canaccord Genuity reiterated a “buy” rating and issued a $60.00 price target (up from $45.00) on shares of Exact Sciences Corporation in a report on Tuesday, October 3rd. Zacks Investment Research upgraded Exact Sciences Corporation from a “hold” rating to a “buy” rating and set a $51.00 price target on the stock in a report on Tuesday, September 26th. Leerink Swann reiterated an “outperform” rating and issued a $50.00 price target (up from $45.00) on shares of Exact Sciences Corporation in a report on Thursday, September 21st. Finally, BidaskClub upgraded Exact Sciences Corporation from a “buy” rating to a “strong-buy” rating in a report on Friday, August 25th. Five equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Exact Sciences Corporation presently has an average rating of “Buy” and an average price target of $43.71.

Exact Sciences Corporation (NASDAQ EXAS) opened at 48.60 on Wednesday. Exact Sciences Corporation has a 12-month low of $13.05 and a 12-month high of $50.65. The stock’s market capitalization is $5.79 billion. The firm’s 50-day moving average price is $43.98 and its 200 day moving average price is $35.76.

Exact Sciences Corporation (NASDAQ:EXAS) last announced its earnings results on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.10. The company had revenue of $57.65 million for the quarter, compared to analyst estimates of $47.73 million. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. On average, equities analysts anticipate that Exact Sciences Corporation will post ($1.18) EPS for the current year.

In other news, SVP D Scott Coward sold 29,115 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total transaction of $1,373,063.40. Following the sale, the senior vice president now owns 64,991 shares of the company’s stock, valued at $3,064,975.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Graham Peter Lidgard sold 81,025 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $3,821,139.00. Following the sale, the insider now directly owns 366,519 shares in the company, valued at approximately $17,285,036.04. The disclosure for this sale can be found here. Insiders have sold 237,444 shares of company stock worth $10,412,421 in the last ninety days. Corporate insiders own 4.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/10/11/exact-sciences-corporation-exas-stake-raised-by-prudential-financial-inc.html.

Exact Sciences Corporation Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.